LEADS BIOLABS-B: LBL-024 administered to the first patient in the Phase II trial for the treatment of biliary tract cancer
I'm PortAI, I can summarize articles.
LEADS BIOLABS-B announced that the PD-L1/4-1BB bispecific antibody LBL-024 has successfully treated the first patient in a Phase II clinical trial for frontline treatment of biliary tract cancer, marking progress in the expansion of the product's indications. The trial is led by Zhongshan Hospital affiliated with Fudan University and aims to evaluate the efficacy and safety of LBL-024 in combination therapy for patients with advanced biliary tract cancer. LBL-024 is expected to become the first approved drug for the treatment of advanced pulmonary neuroendocrine carcinoma
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments